Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is one of the top long-term biotechnology stocks to buy. On October 17, Piper Sandler analyst Yasmeen Rahimi reaffirmed her Buy rating on Avalo Therapeutics Inc. (NASDAQ:AVTX), maintaining a price target of $48, which implies a substantial upside potential of 167.86% from the stock’s current trading levels.

Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)

The buy stance underscores confidence in Avalo’s strategic direction and pipeline progress as it makes progress in immune dysregulation therapies. The analyst’s optimism comes on the heels of recent leadership changes, strategic collaborations, and clinical pipeline development. Avalo’s focus on novel immunology targets and its ability to execute on development milestones were central to Piper Sandler’s bullish outlook.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a biotechnology company focused on developing treatments for immune-mediated inflammatory diseases. Its lead product candidate, AVTX-009, is an anti-IL-1β antibody in a Phase 2 clinical trial for hidradenitis suppurativa (HS). The company’s pipeline also includes other assets, such as quisovalimab and AVTX-008, which are designed to modulate the immune system.

While we acknowledge the potential of AVTX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVTX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.